Several mechanisms of resistance to HER2-targeted therapy mainly include gene mutations leading to protein conformational changes affecting antigen-antibody binding ability, abnormal activation of downstream and bypass signaling pathways, and the failure of the host immune system to mount an appropriate response against HER2-positive cancer cells, etc. (34, 40, 45). This evidence concerns the gene ERBB2 and cancer.